Pulmonx Corporation
LUNG
Rank in Stocks
#18871
Pulmonx Corporation is a biomedical technology firm dedicated to developing and... Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Share Price
$2.80
Last synced: 2026-11-09
Market Cap
$120.26M
Change (1 day)
9.38%
Change (1 year)
33.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pulmonx Corporation (LUNG)
Category
Healthcare
Operating Margin for Pulmonx Corporation (LUNG)
Operating Margin as of November 2026 TTM: -44.39%
According to Pulmonx Corporation's latest financial reports, its current operating margin (TTM) is -44.39%. At the end of 2025 the company had an operating margin of -59.30%.
Operating Margin history for Pulmonx Corporation from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -44.39% | -25.14% |
| 2025 | -59.30% | -13.90% |
| 2024 | -68.87% | -23.64% |
| 2023 | -90.19% | -17.46% |
| 2022 | -109.27% | 11.84% |
| 2021 | -97.70% | -1.08% |
| 2020 | -98.77% | 80.47% |
| 2019 | -54.73% | -27.26% |
| 2018 | -75.24% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.34% |
US
|
|
| 18.08% | -100.41% |
IE
|
|
| 21.25% | -100.48% |
US
|
|
| 21.05% | -100.47% |
US
|
|
| 28.09% | -100.63% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pulmonx Corporation's operating margin
What is Pulmonx Corporation's operating margin?
Pulmonx Corporation's operating margin is -44.39%, as of Nov 2026.
What was Pulmonx Corporation's operating margin in 2025?
In 2025, Pulmonx Corporation's operating margin was -59.30%, compared with -68.87% in 2024.
How has Pulmonx Corporation's operating margin changed since 2020?
From 2020 to 2025, Pulmonx Corporation's operating margin was highest in 2025 (-59.30%) and lowest in 2022 (-109.27%).
How does Pulmonx Corporation's operating margin compare with similar companies?
Pulmonx Corporation's operating margin (-44.39%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.